Pétrault Maud, Gautier Sophie, Bérézowski Vincent, Ouk Thavarak, Bastide Michèle, Pétrault Olivier, Bordet Régis
Inserm U1171 - Degenerative and Vascular Cognitive Disorders, Lille, F-59000, France.
Univ. Lille, Lille, F-59000, France.
Fundam Clin Pharmacol. 2017 Apr;31(2):194-200. doi: 10.1111/fcp.12246. Epub 2016 Oct 25.
Analgesics such as opioid agonists are usually not given during the postoperative phase of experimental stroke because they are susceptible to interfere with the evaluation of neuroprotective therapies. Here, we investigate the potential of acetaminophen and nefopam, two nonopioid analgesic drugs, to exert an analgesic effect without inducing neuroprotection in a murine model of ischemic stroke. We demonstrate that acetaminophen (200 mg/kg, PO) induces a significant decrease in the infarct volume, particularly in the cortex (VEHICLE: 200.1 mm vs.
140.9 mm , P < 0.05), while nefopam (2, 20 or 40 mg/kg, IM), administered at the end of middle cerebral artery occlusion (MCAO), do not influence the infarct size (VEHICLE: 268.6 mm vs. NEFOPAM 2: 248.8 mm , NEFOPAM 20: 250.6 mm and NEFOPAM 40: 215.9 mm , P > 0.05). Moreover, we find that nefopam administration (20 mg/kg, IM) in the acute postoperative phase do not change the level of neuroprotection induced by MK801 (3 mg/kg, IV), a well-known neuroprotectant (VEHICLE: 268.6 mm vs. MK801: 194.4 mm and vs. MK801 + NEFOPAM 20: 195.2 mm ). On the other hand, although nefopam induces analgesia in healthy animals, it is not the case when administered during MCAO (behavior scores at 5 min: HEALTHY: 2.1 vs. HEALTHY + NEFOPAM 20: 0.6, P < 0.5; IR: 0.40 vs. IR + NEFOPAM 20: 0.67, P > 0.05). Our data suggest that neither acetaminophen nor nefopam can be used as analgesic agents to meet the needs of limiting rodent pain and distress during experimental stroke surgery.
在实验性中风的术后阶段,通常不给予阿片类激动剂等镇痛药,因为它们容易干扰神经保护疗法的评估。在此,我们研究了对乙酰氨基酚和奈福泮这两种非阿片类镇痛药在不诱导神经保护的情况下,在缺血性中风小鼠模型中发挥镇痛作用的潜力。我们证明,对乙酰氨基酚(200毫克/千克,口服)可使梗死体积显著减小,尤其是在皮质(对照组:200.1立方毫米 vs. 对乙酰氨基酚组:140.9立方毫米,P < 0.05),而在大脑中动脉闭塞(MCAO)结束时给予奈福泮(2、20或40毫克/千克,肌肉注射)并不影响梗死大小(对照组:268.6立方毫米 vs. 奈福泮2毫克/千克组:248.8立方毫米,奈福泮20毫克/千克组:250.6立方毫米,奈福泮40毫克/千克组:215.9立方毫米,P > 0.05)。此外,我们发现术后急性期给予奈福泮(20毫克/千克,肌肉注射)不会改变著名神经保护剂MK801(3毫克/千克,静脉注射)诱导的神经保护水平(对照组:268.6立方毫米 vs. MK801组:194.4立方毫米,vs. MK801 + 奈福泮20毫克/千克组:195.2立方毫米)。另一方面,虽然奈福泮在健康动物中可诱导镇痛,但在MCAO期间给药时并非如此(5分钟时行为评分:健康组:2.1 vs. 健康 + 奈福泮20毫克/千克组:0.6,P < 0.5;缺血组:0.40 vs. 缺血 + 奈福泮20毫克/千克组:0.67,P > 0.05)。我们的数据表明,对乙酰氨基酚和奈福泮都不能用作镇痛药来满足在实验性中风手术期间限制啮齿动物疼痛和痛苦的需求。